vimarsana.com

Page 22 - ஜப்பான் அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RepliCel Life Sciences, Inc : RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor

RepliCel Life Sciences, Inc.: RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor VANCOUVER, BC / ACCESSWIRE / May 17, 2021 / RepliCel Life Sciences Inc. (OTCPINK:REPCF) (TSXV:RP) (FRA:P6P2) ( RepliCel or the Company ), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that Professor Akimichi Morita, one of Japan s leading dermatology research clinicians, has agreed to be RepliCel s clinical advisor for the development and commercialization of its skin rejuvenation product (RCS-01) in Japan. The Company, working with industry leaders, CJ Partners, and clinical research organization, Accerise, is currently preparing to support the next-phase clinical research study of its skin rejuvenation cell therapy, RCS-01, in Japan under the Act for Safety of Regenerative Medicine (ASRM) that, upon successfully meeting its endpoints, could lead to a commercial launch of the product in Japan.

Japan s Ministry of Health, Labour and Welfare Grants Priority Review for Enfortumab Vedotin New Drug Application

Japan s Ministry of Health, Labour and Welfare Grants Priority Review for Enfortumab Vedotin New Drug Application NDA, submitted in March, is for locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication News provided by Share this article Share this article TOKYO, May 13, 2021 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas ) today announced Japan s Ministry of Health, Labour and Welfare (MHLW) has granted priority review for the company s New Drug Application (NDA), which was submitted in March. If approved, enfortumab vedotin would be the first antibody-drug conjugate (ADC) available in Japan for the treatment of patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication.

Halozyme Therapeutics Inc (HALO) Q1 2021 Earnings Call Transcript

Halozyme Therapeutics Inc (HALO) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Halozyme Therapeutics Inc (NASDAQ: HALO) Q1 2021 Earnings Call Operator Good day, and thank you for standing by. Welcome to the Halozyme First Quarter 2021 Financial Results Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Al Kildani, Vice President of Investor Relations and Corporate Communications. Thank you. Please go ahead.SPONSORED: 10 stocks we like better than Halozyme Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade,

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.